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The classification and treatment of 
antibody-mediated renal allograft 
injury: Where do we stand?
V Nickeleit1 and K Andreoni2
Since the acceptance of the detection of C4d in allografts as a reliable 
tool to mark a humoral alloresponse, de novo antibody-induced graft 
injury has attracted much attention. Antibodies and B cells are the new 
frontier in transplantation. At this juncture carefully designed studies 
are critical in order to gain solid diagnostic, therapeutic, and prognostic 
knowledge about the role of antibodies in graft injury and to avoid any 
confusion and misconception. One prerequisite is the strict adherence to 
refined classification systems of renal transplant rejection that carefully 
split and categorize different phenotypes of humoral mediated graft 
damage and ideally also include information on anti-donor antibody 
specificity and titers. Sun and colleagues follow this concept and provide 
evidence that mixed cellular and antibody-mediated graft rejection can 
respond favorably to intensified immunosuppression with tacrolimus 
and mycophenolate mofetil. What will the future bring to treat rejection 
episodes with a dominant, co-dominant, or minor antibody reponse?  
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Many diff erent injuries can aff ect renal allo-
graft s, most importantly rejection. At any 
time in history our depth of understand-
ing and our pathophysiologic concepts 
of rejection are best refl ected by the way 
rejection episodes are classifi ed. Th e clas-
sifi cation systems and our nomenclature 
heavily infl uence therapeutic strategies at 
the individual patient level as well as out-
come analyses of multicenter drug trials.
The gold standard to diagnose and 
classify rejection is based on histologic 
changes. The current most commonly 
used classification scheme of kidney 
transplant rejection is the ‘Banff  system’, 
which was fi rst introduced in 1993 and has 
subsequently undergone several modifi ca-
tions, the last one in 2003.1,2 ‘Banff ’ has 
had a major impact because it succeeded 
in standardizing diagnostic terms and 
thus made direct data comparison of 
multicenter trials and scientifi c publica-
tions possible. However, the nomencla-
ture used and our classifi cation attempts 
are dynamic makeshift constructs that 
are heavily infl uenced not only by experi-
ence, technology, and knowledge, but also 
by convention, trends, and opinions. Th e 
latter factors are most problematic.
For example, traditionally rejection epi-
sodes have been histologically categorized 
on the basis of clinical terms into two major 
subgroups: ‘acute’ and ‘chronic’, Th ese clini-
cal terms are, however, ill suited for classify-
ing histologic lesions. ‘Acute’ and ‘chronic’ 
changes are oft en not sharply separated 
entities but rather represent a continuum 
with early infi ltrative infl ammatory lesions 
(such as endothelialitis/Banff  type II rejec-
tion) seen at one end of the spectrum, a 
mixed pattern with sclerosis and infl am-
mation seen during disease progression 
(such as smoldering rejection), and inac-
tive fi brosis (such as arterial intimal sclero-
sis without infl ammation) in the ultimate 
‘chronic’ scarring stage.3,4 Although impre-
cise and misleading, ‘acute’ and ‘chronic’ 
rejection are important clinical buzzwords 
that seem to be ineradicable.
Similarly problematic are two other 
categories oft en used to classify rejection: 
cellular and humoral. ‘Acute cellular’ rejec-
tion (ACR) has been a trendy term over the 
last 30 years, being used as a caption for 
(1) tubulointerstitial rejection, that is, Banff  
type I; (2) transplant endarteritis, that is, 
Banff  type II rejection; and (3) transplant 
glomerulitis.5,6 It was argued that the 
presence of lymphocytic infiltrates and 
the good response to anti-T cell treatment 
strategies favored a ‘cell-mediated immune 
response.’5 On the other hand, antibody-
mediated injury, oft en due to pre-formed 
antibodies, was believed to be the cause of 
Banff  type III rejection with fi brinoid arte-
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Figure 1 | Donor-specific antibodies 
and histologic changes. Donor-specific 
antibodies (C4d positivity) can be found in 
association with different histologic changes 
and even in the setting of normal histology. 
Only a minority of acute-rejection episodes 
represent ‘pure’ T cell-poor, C4d-positive, 
antibody-mediated acute rejection (see Figure 
2). The immune status, antibody titers, and 
antibody specificity influence the histologic 
phenotype and clinical dominance.
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rial wall necrosis, and rare forms of hypera-
cute and accelerated acute rejection.5
In 1993, H. Feucht, from Munich, pub-
lished one of his major landmark papers 
on the complement degradation product 
C4d and its accumulation in renal allo-
graft s, challenging the concept of a sharp 
separation between ‘cellular’ and ‘humoral’ 
rejection.7 Feucht reported that the 
immunohistochemical detection of C4d 
in kidney transplants was a marker for an 
antibody-mediated alloresponse that was 
seen with various histologic changes and 
indicated inferior graft  survival. However, 
Feucht’s work remained largely unrecog-
nized. It took six years and several Banff  
meetings before his pioneering observa-
tions became noticed on a broader scale 
and until ‘C4d’ was ultimately incorpo-
rated into the 2003 update of the Banff  
classifi cation system.2 Although much 
remains to be learned about C4d and cir-
culating donor-specifi c antibodies in the 
future, the immunohistochemical detec-
tion of C4d is undoubtedly a very help-
ful tool to diagnose not only graft  injury 
induced by pre-formed antibodies but, in 
particular, a de novo antibody response 
mounted aft er transplantation.8,9
At present — under the infl uence of C4d 
— it seems that we have (re)discovered the 
importance of (de novo) antibody-medi-
ated graft  injury. Humoral/antibody-medi-
ated rejection (AMR) is the new trendy 
term, and all C4d-positive cases, regardless 
of concurrent histologic changes, are cur-
rently oft en classifi ed as AMR, especially 
if circulating donor-specifi c antibodies are 
also detected. Th is simplistic view is fueled 
by recent consensus guidelines giving 
broad defi nitions of AMR10 such as “the 
primary biopsy features of antibody medi-
ated rejection are detection of the com-
plement component C4d in peritubular 
capillaries combined with some evidence 
of acute tissue injury….”11 Recommen-
dations that AMR is found not only in a 
‘pure’ form (Banff  category 2 rejection) but 
frequently in association with cellular11–14 
and/or sclerosing rejection15 are much too 
oft en ignored. But is the practice of using 
the term ‘AMR’ in a broad way logical, help-
ful, and constructive to better understand 
biological events leading to graft  injury, to 
accurately defi ne changes, and to develop 
new, tailored immunosuppressive treat-
ment protocols? We do not think so.12
De novo antibody formation/C4d posi-
tivity can oft en be seen as an independent 
immune response coinciding with various 
histologic changes and allograft  dysfunc-
tion (Figure 1). Circulating donor specifi c 
antibodies and C4d positivity are associ-
ated with different degrees of a cellular 
alloresponse ranging from no T-cell infi l-
trates to Banff  borderline changes (category 
3) and tubulo-interstitial cellular rejection 
or transplant endarteritis (category 4). 
Depending on the circulating antibody 
titers, the specifi city, and the host immune 
status, the alloantibody response can be 
clinically more or less signifi cant. 
A dominant de novo antibody response 
results in ‘pure,’ T cell-poor, C4d-positive 
AMR with acute tubular injury, hemor-
rhage, and occasional thrombus forma-
tion in small-caliber vessels/capillaries 
(Banff category 2, types I and II rejec-
tion; Figure 2) . Major histocompatibility 
complex class II (HLA-DR) is typically 
not expressed in tubular epithelial cells.12 
Although these ‘pure’ T cell-poor, C4d-pos-
itive rejection episodes are the prototypes of 
antibody-mediated graft  injury (disregard-
ing hyperacute rejection with pre-formed 
antibodies or ABO-incompatible graft ing), 
they are rather uncommon, accounting for 
only approximately 5%–10% of all episodes 
of ‘acute’ rejection.12 Th ey frequently occur 
during the fi rst weeks aft er transplantation, 
especially in presensitized recipients, and 
require specifi c therapy (see below). 
Much more common are mixed rejec-
tion episodes with a cellular or sclerosing 
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Figure 2 | ‘Pure,’ T cell-poor antibody-mediated rejection (AMR). (a, b) Light microscopy. 
The interstitial compartment (I) shows focal edema and mixed inflammatory-cell infiltrates with 
polymorphonuclear leukocytes surrounding tubules (T) in a finger-like fashion. Some tubules 
demonstrate signs of acute epithelial-cell injury; tubulitis is not detected. Small fibrin thrombi are 
noted in glomerular capillaries (G, arrows), but not in an intraparenchymal artery (V). Periodic acid-
Schiff-stained sections; original magnification, ×250. (c,d) Immunofluorescence microscopy. 
(c) C4d is diffusely found along peritubular capillaries (G, glomerulus). Original magnification, ×200. 
(d) Major histocompatibility complex class II (HLA-DR) is not expressed by tubular epithelial cells 
(T, tubulus). Original magnification, ×300. The patient presented with abrupt, severe deterioration 
of renal function 7 days after transplantation; at the time of biopsy, high titers of anti-donor class II 
antibodies were found (anti-DR14,15, -DRw51,52, and -DQw1), and panel-reactive antibody (PRA) 
titers had risen from 0% at the time of grafting to 45%. Plasmapheresis and rituximab therapy were 
initiated; the graft was lost 10 days after biopsy because of infection.
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component and an associated codominant 
alloantibody response (C4d positive), as 
illustrated by Sun and colleagues in this 
issue of Kidney International.16 Approxi-
mately 20%–30% of cases with cellular 
tubulointerstitial rejection (Banff  category 
4, type I), 40%–50% of biopsies with trans-
plant endarteritis (Banff  category 4, type II; 
Figure 3), and 60% of graft s with transplant 
glomerulitis are C4d positive and fall into 
the mixed ACR–AMR rejection groups12–14 
that typically also express the  major his-
tocompatibility complex class II in tubular 
cells (HLA-DR; Figure 3).12,17 Th ese mixed 
rejections are clinically more severe than 
the corresponding antibody/C4d-nega-
tive ACR episodes;14 they can respond 
to intense anti-T cell therapy with good 
outcome reported in some studies,13,18 
including Sun and colleagues’ current 
publication.16 Thus, de novo antibody-
mediated renal allograft  injury can present 
as ‘pure’ or ‘mixed’ rejections (Figure 4) 
that are only imperfectly characterized by 
the generic term ‘AMR.’ Mixed rejections 
require targeted treatment approaches.
Th e clinical treatments for ‘acute’ rejec-
tion are numerous. In practice, treatment 
protocols vary according to the time from 
transplantation; the histologic diagnosis 
across the spectrum from ACR to mixed 
ACR–AMR to ‘pure’ T cell-poor AMR; 
the patient’s history of antibody sensitiza-
tion and prior rejection history; the recent 
maintenance immunosuppression regimen; 
and proximity to, and type of, induction 
therapy. For example, early CD68+ mono-
cytic ACR early aft er Campath induction 
without maintenance calcineurin inhibi-
tor tends to respond to intravenous steroids 
and calcineurin-inhibitor introduction.19,20 
Banff  type I tubulointerstitial ACR (C4d 
negative) within the fi rst 6 months aft er 
transplantation will often respond to 
intravenous steroids and increased main-
tenance immunosuppression. Banff  type II 
transplant endarteritis ACR (C4d negative) 
typically requires anti-lymphocyte deplet-
ing antibody treatment.21
Antibody-mediated graft  injury tends 
to behave diff erently across the spectrum 
from mixed ACR–AMR with a dominant 
cellular component, to mixed ACR–AMR 
with high donor-specifi c antibody (DSA) 
titers, specifically those to DRw51, -52, 
or -53, to ‘pure’ T cell-poor AMR (also 
see Figure 4).22 A mixed ACR–AMR 
(tubulointerstitial rejection or transplant 
endarteritis, C4d positive) is most com-
monly treated with a full course of an 
anti-lymphocyte depleting agent, such as 
thymoglobulin.13,18 Th is therapy can clear 
both the cellular and the humoral com-
ponents of the rejection. It is tempting to 
hypothesize that the antibody component 
in these mixed rejection episodes is highly 
dependent on local graft  cellular stimula-
tion or ‘help’ and thus regresses with potent 
anticellular therapy. Polyclonal antibodies 
may also target B cells and plasma cells 
directly to some extent. ‘Rescue’ therapy 
with tacrolimus and mycophenolate 
mofetil has been reported previously in 
mixed sclerosing and antibody-mediated, 
C4d-positive rejection episodes (so-called 
chronic humoral rejection23) and now by 
Sun et al.16 also in cases of mixed ACR–
AMR, underscoring the importance of the 
T-cell response in these lesions. Whether 
treatment strategies with high-dose (long-
term) tacrolimus and mycophenolate 
mofetil are a better alternative to (short-
term) anti-lymphocyte depleting agents 
appears doubtful, however, as the former 
drug regimen is thought to be associated 
with an increased risk for polyoma-BK-
virus nephropathy.24–28 Failure of the C4d 
to disappear aft er 3–4 weeks and/or the 
DSA titers to decrease to very low levels in 
the clinical setting of continuous allograft  
dysfunction should trigger more aggressive 
treatments as a second therapeutic step — 
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Figure 3 | Mixed acute cellular and antibody-mediated rejection (mixed ACR–AMR). (a, b) 
Light microscopy. An intraparenchymal artery (V) shows marked transplant endarteritis (arrows; 
note: intimal inflammation is superimposed on donor arteriosclerosis). The interstitium reveals 
pronounced, diffuse, predominantly mononuclear inflammatory-cell infiltrates and tubulitis 
(T, tubulus; the arrowheads mark the tubular basement membranes of severely inflamed tubular 
cross sections). Glomeruli (G) are without significant alterations. These light microscopic changes 
can be classified as a Banff category 4, type II acute-rejection episode. Periodic acid-Schiff-stained 
sections; original magnifications, ×200 (a) and ×300 (b). (c,d) Immunofluorescence microscopy. (c) 
C4d is diffusely found along peritubular capillaries marking additional antibody-mediated injury (G, 
glomerulus). Original magnification, ×200. (d) Major histocompatibility complex class II (HLA-DR) is 
expressed by tubular epithelial cells (T, tubulus) in cases of cellular rejection. Original magnification, 
×300. The patient presented with deterioration of renal function 18 days after transplantation; at the 
time of biopsy, high titers of anti-donor class I antibodies were found (anti-A2). Thymoglobulin and 
subsequently plasmapheresis and rituximab therapy were initiated; the graft was lost 17 days after 
biopsy because of rejection.
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that is, plasmapheresis and/or intravenous 
immunoglobulin therapy.
There are multiple approaches to a 
high-titer DSA-dominant, C4d-positive, 
rejection episode (most typically seen as 
a ‘pure,’ T cell-poor AMR, rarely as mixed 
ACR–AMR). In the setting of profound 
allograft dysfunction, most clinicians 
favor rapid removal and/or neutralization 
of the circulating antibodies with plas-
mapheresis and/or intravenous immu-
noglobulin.22,29,30 Plasmapheresis with 
low-dose intravenous immunoglobulin 
has the theoretical advantage of remov-
ing circulating antibody and providing 
third-party pooled intravenous immu-
noglobulin for intra-apheresis neutraliza-
tion and possible immunomodulation of 
antibody production through Fc receptor 
negative-feedback loops.30 Th e addition of 
anti-CD20 (rituximab) has been discussed 
in the treatment of B cell-rich cellular 
rejection (C4d negative) as well as ‘pure’ 
T cell-poor AMR (C4d positive) with the 
aim to reduce the number of B cells.31–33 
However, plasma cells are not aff ected, and 
rituximab may have little eff ect on circulat-
ing donor-specifi c antibodies.33
The classification and treatment of 
antibody-mediated renal allograft  injury: 
where do we stand? At the beginning! 
Over the past years we have learned that 
de novo antibody formation aft er trans-
plantation can result in graft  injury that is 
characterized by the accumulation of C4d 
along peritubular capillaries and various 
histologic changes. It has become obvi-
ous that all antibody-containing rejection 
episodes are not equal; thus a simplistic 
diagnosis of ‘antibody-mediated rejection’ 
and standard therapy with plasmapheresis 
are inadequate. Rather, we are in the ‘split-
ting’ stage, requiring a refi ned approach to 
diagnosis and therapy in order to improve 
our knowledge, as illustrated by Sun and 
colleagues’ article.16 In the management 
of kidney-transplant recipients, DSA 
monitoring should become as standard as 
a graft  biopsy once C4d is detected. Fol-
low-up graft  biopsies and serial measure-
ments of circulating DSA aft er treatment of 
C4d-positive rejection episodes should be 
performed because of the unpredictability 
of the alloantibody response to treatment. 
Th e B cell is back; let’s face the challenge in 
a systematic fashion!
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Regional mortality differences in 
end-stage renal disease: How far 
can observational studies take us?
CP Kovesdy1
The survival of patients with ESRD living in various geographic regions 
is strikingly different. Efforts to determine the reasons behind this 
observation have been hampered by difficulties in adjusting for many 
characteristics that are inherently different in patient populations living 
on different continents. The mortality rate for the general population 
in a given region could be used to adjust for risk factors that would be 
otherwise difficult to quantify.
Kidney International (2007) 71, 11–12. doi:10.1038/sj.ki.5001685
Geographical diff erences in the mortal-
ity rate of patients with end-stage renal 
disease (ESRD) have been described for 
more than a decade. In a study by Held 
et al.,1 the risk of mortality for patients 
on dialysis in the United States was 15% 
higher than the risk in Europe and 33% 
higher than that in Japan. Th e nephrol-
ogy community received this observation 
with great interest, as it held the promise 
of identifying modifi able factors associ-
ated with mortality in ESRD. There is 
great variability in ESRD practice patterns 
across diff erent continents, even though 
randomized controlled trials underlying 
these patterns are scarce. It thus seemed 
plausible to speculate that the diff erent 
ways we treat our patients might be at 
least in part responsible for the discrep-
ant mortality rates observed. In order to 
identify modifi able factors responsible for 
mortality, one would have to account for 
all the non-modifi able diff erences between 
the studied patient populations, a diffi  cult 
task when patients are from diff erent con-
tinents. Th is was clearly a challenge in the 
study by Held et al.,1 as their data were 
obtained from diff erent reporting systems 
and contained few variables to character-
ize the patient populations studied. Th e 
Dialysis Outcomes and Practice Patterns 
Study (DOPPS) off ered the ideal remedy 
for this problem, as it uniformly recorded 
patient outcomes from dialysis units in 
Europe, Japan, and the United States, and 
it was also able to describe the character-
istics of the diff erent patient populations 
in extensive detail.2 Not unexpectedly, it 
became clear that all ESRD patients are not 
equal: racial composition in various geo-
graphical areas is obviously diff erent, and 
patients in the United States are older and 
have a higher burden of comorbidities.3 
Detailed adjustment for this heterogeneity 
alleviated somewhat the transcontinental 
mortality gap, but the diff erence remained 
signifi cant nevertheless, again suggesting 
that variability in individual patient char-
acteristics alone is not suffi  cient to explain 
the observed geographical diversity.3
Another seemingly plausible, yet very 
diffi  cult-to-quantify, factor impacting 
on regional death-rate diff erences is the 
eff ect on mortality imparted by the sum 
of all the geographical, environmental, 
cultural, and socioeconomic eff ects that 
are unique to any given area. Diff erences 
in genetics, income level, diet and life-
style, crime rate, access to health care, or 
air quality could all be important, yet it 
seems impossible to adjust for all these 
(and probably many more) individual 
factors when comparing the risk of 
mortality in patients from areas far from 
each other. Van Dijk et al.4 (this issue) 
off er a simple and elegant solution to this 
problem: they used general population 
mortality rates as surrogate adjustment 
for a host of diffi  cult-to-measure factors, 
assuming that all or most of these factors 
have a similar impact on people living 
in the same area, including patients with 
ESRD. Th e authors compared mortal-
ity rates in patients with ESRD and in 
the general population across a north–
south divide in Europe and showed that 
general population mortality differ-
ence accounted for 26% of the regional 
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